

A new project, MOPEAD – Models of Patient Engagement for Alzheimer’s Disease, started in October 2016.

This 33-month project aims to deliver a step-change in Alzheimer’s disease (AD) patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis.

Multiple regional project sites will be established to identify and test models of efficient early identification of mild AD dementia and prodromal AD patients. These models will be compared and contrasted to identify ways to improve early detection and diagnosis of AD. The findings will enable models of patient access to be established and used in the broader AD community.

Ultimately, MOPEAD will respond to the urgency of finding interventions to halt AD by stimulating a faster recruitment of patients into clinical trials.

MOPEAD will contribute to the imperative to finding interventions to halt AD. Dementia affects over 35 million people globally, a figure set to rise to over 115 million by 2050 due to the ageing of the population. AD has a huge and growing burden on health and social systems, the families and carers of those affected. Despite decades of research, there is still no treatment nor cure for the disease. It is therefore crucial to determine interventions that will help identify hidden cases of AD through patient engagement and provide new insights for therapeutic interventions in clearly identified populations.

MOPEAD partners are Fundació ACE Institut Català de Neurociències Aplicades, Eli Lilly and Company Ltd, ASDM Consulting, AstraZeneca AB, European Institute of Women’s Health, GMV Soluciones Globales Internet S.A.U., Karolinska Institutet, KITE Innovation (Europe) Ltd, Spomincica—Alzheimer Slovenia, University Hospital of Cologne, University Medical Centre Ljubljana, Fundacio Hospital Universitari Vall D’Hebron—Institut de Recerca, Stichting VUmc, Alzheimer Europe.

www.mopead.eu

@MopeadEU

Disclaimer

This communication reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

Notes to Editors

About Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between

the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

www.imi.europa.eu